Paclitaxel allergic reactio
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2021/07/034839
- Lead Sponsor
- CI AIIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Adults patients with age between 18 years to 70 years
Histopathological diagnosis of cancer
Willing to participate and to give written informed consent
Naïve to conventional paclitaxel chemotherapy and planned to receive conventional paclitaxel either as single agent or in combination
ECOG performance status 0-2
Stable baseline vital signs: Afebrile, radial artery blood pressure (90/60 â?? 130/90mm Hg), pulse rate 60 â?? 100 / minutes, respiratory rate 12-18/ minutes, 97.8 °F to 99.1 °F (36.5° C to 37.3° C);
Past history of hypersensitivity reaction to paclitaxel or cremophor containing drugs (cyclosporine, propofol, diazepam, teniposide, etoposide, Vitamin K) or partner drug or pheniramine or ranitidine
On chronic systemic steroids or received any dose in the last week
No history of hypersensitivity to partner drug
Hb < 8gm/dl, ANC < 1000/m3, creatinine > 2mg/dl, Bilirubin > 5 X ULN, transaminases 10 times or more
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method